Vita Coco Faces Legal and Revenue Storm—But Can It Defend Its Premium?

The stock's sharp decline to a 52-week low is a direct reaction to a dual shock: a formal fraud probe and a concrete revenue shortfall risk. The catalyst broke in late March 2026, with the stock falling $5.26 per share, or about 9% from a close of $58.14 on March 17 to $52.88 on March 20. This move aligns with the market digesting a negative report from NINGI Research, which had been published a year earlier but gained new traction.

The core event is a fraud probe launched on March 26, 2026 by Pomerantz Law Firm, investigating claims of securities fraud and misleading growth statements. This legal action centers on the NINGI Research report from March 26, 2025, which alleges Vita Coco misled investors. The report's most damaging claim is that the company was set to lose a key contract with Costco, its largest private-label customer, despite a renewal in 2023. The report estimated this loss would cause an estimated $90 million revenue shortfall for Vita Coco by the end of 2025.

The tactical question now is whether this is a temporary mispricing or a fundamental reset. The probe adds legal and reputational pressure, while the $90M shortfall represents a tangible, near-term financial hit. For a stock already trading at a discount, this news forces a reassessment of the company's growth narrative and operational integrity.

The Financial Mechanics: Separating the $90M Risk from the Business

The alleged $90 million revenue shortfall is a concrete threat, but its impact must be measured against the company's scale and its valuation demands. That figure represents roughly 17.4% of Vita Coco's 2024 revenue of $516 million. For a business with a market cap near $3.2 billion, it's a significant hit, but not an existential one. The real question is whether this loss derails the growth trajectory the stock's premium is betting on.

The stock's current price near the 52-week low highlights the market's volatility and the high stakes. The share price has swung from a low of $25.79 to a high of $61.39, with the current level about 51% below the peak. This wide range shows how sensitive the stock is to news. The probe and the revenue risk have clearly triggered a reset, but the magnitude of the drop suggests the market is pricing in a much larger problem than a single contract loss.

The valuation tells the rest of the story. With the stock trading at roughly 47 times earnings, the company must maintain high growth to justify its price. The market is already skeptical; the stock's year-to-date gain has slowed to 55% after a stellar five-year run. Any slowdown in the mid-teens growth trajectory could pressure that multiple, making the $90M risk a catalyst for a further valuation reset, not just a one-time accounting hit.

The bottom line is that the Costco contract risk is a material near-term headwind. But for the stock to hold its ground, Vita Coco must demonstrate it can still grow at a pace that supports its premium valuation, even after absorbing this loss. The probe adds uncertainty, but the financial mechanics point to a battle for growth, not a battle for survival.

Catalysts and Risks: What Moves the Stock Next

The tactical setup now hinges on two near-term events that will either confirm the market's worst fears or provide a path to stabilization. The primary catalyst is the company's official response to the fraud probe. Vita Coco has not yet commented publicly on the Pomerantz Law Firm investigation launched on March 26, 2026. A clear, forthright statement addressing the core allegations-particularly the claim of a lost Costco contract-could immediately reduce the legal overhang and sentiment risk. Conversely, silence or a defensive rebuttal may fuel further speculation and keep the stock under pressure.

The second key data point is the Q1 2026 earnings report, expected in late April or early May. This release will provide the first official financial look at the alleged $90 million revenue shortfall. Management's guidance on the Costco contract status and overall growth trajectory will be critical. Analysts project continued mid-teens growth for 2026, so any deviation from that path, or acknowledgment of the contract loss, will directly challenge the growth narrative that supports the stock's premium valuation.

The primary risk is that the fraud allegations gain serious traction. The Pomerantz probe follows a similar investigation by Levi & Korsinsky. If these investigations lead to a certified class-action lawsuit, it would create a prolonged legal overhang that caps the stock's upside potential. Even if the revenue risk is mitigated, the legal uncertainty could keep the stock range-bound for months. The Schall Law Firm's recent reminder about a class action against another company underscores the active landscape for such litigation .

The bottom line is that the stock's next move is binary. A credible response and solid Q1 guidance could spark a relief rally from the 52-week low. But if the company fails to address the probe or confirms the revenue hit, the multiple compression and legal fears could drive the stock even lower. For now, the setup is defined by waiting for these catalysts to resolve the uncertainty.